Short-term Bactericidal Effect of Contezolid in MAC-PD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

188 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-24

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if contezolid works to treat mycobacterium avium complex pulmonary disease in adults. It will also learn about the safety of contezolid. The main questions it aims to answer are:

Does adding contezolid to standard regimen further decrease the bacterial load in patients' sputum compared with current standard regimen? What medical problems do participants have when taking contezolid along with standard regimen? Researchers will compare standard regimen plus contezolid to standard regimen alone to see if contezolid helps further lower the count of bacteria in patients' sputum.

Participants will:

Take contezolid and standard regimen (azithromycin, ethambutol and rifampicin) or standard regimen only for 6 months, contezolid is administered every day while other drugs are taken 3 times a week Visit the clinic once every 1 month for checkups and tests.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

NCT07213765

Mycobacterium Avium Complex Pulmonary Disease

RECRUITING PHASE4

TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).

NCT00449644

Tuberculosis

COMPLETED PHASE2

To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmonary MDR-TB.

NCT00910871

Tuberculosis

COMPLETED PHASE2

Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis

NCT06811025

Tuberculosis Meningitis

ENROLLING_BY_INVITATION PHASE1/PHASE2

Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease

NCT05824988

Mycobacterium Avium Complex Mycobacterium Avium-Intracellulare Infection Gram-Positive Bacterial Infections +1 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mycobacterium Avium Complex Pulmonary Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Contezolid plus standard regimen

Participants in this arm will receive contezolid 800mg po q12h, azithromycin 500mg po tiw (250mg po tiw if weight below 50kg), rifampicin 600mg po tiw and ethambutol 25mg/kg po tiw for 6 months.

Group Type EXPERIMENTAL

Contezolid

Intervention Type DRUG

contezolid 800mg po q12h for 6 months

Azithromcyin

Intervention Type DRUG

azithromycin 500mg po tiw (250mg po tiw if weight below 50kg) for 6 months.

Rifampicin (RIF)

Intervention Type DRUG

rifampicin 600mg po tiw for 6 months.

Ethambutol

Intervention Type DRUG

ethambutol 25mg/kg po tiw for 6 months.

Standard regimen

Participants in this arm will receive azithromycin 500mg po tiw (250mg po tiw if weight below 50kg), rifampicin 600mg po tiw and ethambutol 25mg/kg po tiw for 6 months.

Group Type ACTIVE_COMPARATOR

Azithromcyin

Intervention Type DRUG

azithromycin 500mg po tiw (250mg po tiw if weight below 50kg) for 6 months.

Rifampicin (RIF)

Intervention Type DRUG

rifampicin 600mg po tiw for 6 months.

Ethambutol

Intervention Type DRUG

ethambutol 25mg/kg po tiw for 6 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Contezolid

contezolid 800mg po q12h for 6 months

Intervention Type DRUG

Azithromcyin

azithromycin 500mg po tiw (250mg po tiw if weight below 50kg) for 6 months.

Intervention Type DRUG

Rifampicin (RIF)

rifampicin 600mg po tiw for 6 months.

Intervention Type DRUG

Ethambutol

ethambutol 25mg/kg po tiw for 6 months.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients voluntarily participate in this study and sign the Informed Consent Form.
2. Age ≥ 18 years and ≤75 years; gender unrestricted.
3. Confirmed diagnosis of MAC pulmonary disease per ATS/IDSA 2020 guidelines or Chinese Guidelines for Diagnosis and Treatment of Nontuberculous Mycobacterial Diseases (2020 edition), with imaging features consistent with nodular bronchiectatic type.
4. No prior anti-MAC treatment within the 3 months preceding screening.
5. For premenopausal women of childbearing potential who are not surgically sterile:

Must use a medically accepted contraceptive method (e.g., intrauterine device, hormonal contraception, or condom) during the study period and for 3 months following the last dose of investigational treatment.

Serum or urine human chorionic gonadotropin (hCG) test must be negative within 72 hours prior to enrollment.

Must not be breastfeeding. Male patients with partners of childbearing potential must use effective contraception during the study period and for 3 months after the last dose.
6. Organ function criteria met within one week prior to enrollment:

i. Hemoglobin ≥60 g/L; ii. Neutrophil count ≥0.5 × 10⁹/L; iii. Platelet count ≥60 × 10⁹/L; iv. Serum total bilirubin ≤3 × upper limit of normal (ULN); v. Aspartate aminotransferase (AST) ≤3 × ULN; vi. Alanine aminotransferase (ALT) ≤3 × ULN; vii. Serum creatinine \<2 × ULN OR creatinine clearance ≥60 mL/min; viii. Blood urea nitrogen (BUN) ≤200 mg/L; ix. Urinalysis: Proteinuria \<++; if proteinuria is +, 24-hour total protein must be \<500 mg.

x. Fasting blood glucose within normal range OR stable glycemic control in diabetic patients.

xi. Cardiac function: No myocardial infarction in the preceding 6 months; No unstable angina or severe arrhythmias; New York Heart Association (NYHA) functional class \>II.

Exclusion Criteria

1. History of allergy to any study drug in the treatment regimen.
2. Mixed infections with multiple mycobacteria, bacteria, fungi, or viruses (e.g., HIV coinfection).
3. Presence of congenital/acquired immunodeficiency disorders, active pulmonary malignancy (primary or metastatic), or other malignancies requiring chemotherapy/radiation therapy during the screening or study period.
4. History of solid organ transplantation.
5. Currently undergoing dialysis.
6. Uncontrolled radiation pneumonitis requiring steroid or immunoglobulin pulse therapy, active interstitial lung disease with clinical evidence, uncontrolled and significant pleural effusion or pericardial effusion.
7. Unstable systemic comorbidities including:

Hypertensive crisis; Unstable angina; Congestive heart failure (NYHA Class III/IV); Myocardial infarction within the preceding 6 months; Severe psychiatric disorders requiring medication (e.g., schizophrenia, bipolar disorder); Severe hepatic or renal dysfunction (e.g., Child-Pugh Class C cirrhosis, eGFR \<30 mL/min/1.73m²); Neurodegenerative diseases (e.g., Alzheimer's disease).
8. Poor gastrointestinal function or malabsorption syndrome.
9. Receipt of other investigational drugs within 4 weeks prior to the first study drug administration.
10. Concurrent participation in another interventional clinical trial, unless it is an observational/noninterventional study OR follow-up phase of a completed intervention trial.
11. Any physical examination findings or clinical tests deemed by the investigator as likely to:

Interfere with study results; Increase risks of complications during treatment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No